ABBV - CIK 0001551152
The table below shows AbbVie Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B |
| Capital expenditure | $1.21B | $974.00M | $777.00M | $695.00M | $787.00M | $798.00M |
| Investing cash flow | -$6.64B | -$20.82B | -$2.01B | -$623.00M | -$2.34B | -$37.56B |
| Dividends paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B |
AbbVie Inc. reported operating cash flow of $19.03B for fiscal year 2025. That is up 1.2% from $18.81B in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from $9.96B (FY 2017) to $19.03B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.72B |
| Stock buybacks | $980.00M | $1.71B | $1.97B | $1.49B | $934.00M | $978.00M |
| Financing cash flow | -$12.72B | -$5.21B | -$17.22B | -$24.80B | -$19.04B | -$11.50B |